BridgeBio Pharmaceuticals: Initiation Of Coverage- A Closer Look At Its Scientific Advancements & Pipeline Developments! 

BridgeBio Pharma delivered strong second-quarter results, emphasizing significant progress in both its commercial operations and pipeline development. The company’s lead product, Attruby, used in the treatment of ATTR cardiomyopathy, exhibited robust growth. In Q2 2025, Attruby generated $78 million in global sales, with $71.5 million from U.S. net sales, reflecting 100% growth over the previous quarter. This growth was driven by an increase in the number of unique patient prescriptions and prescribers, indicating solid market penetration. However, the market also saw the entry of a new competition, suggesting an evolving competitive landscape.